Judith Mitchell joined the Next Science team as Managing Director in August 2017. Previously, as President of Depuy Synthes Asia Pacific, Ms. Mitchell lead the Orthopaedics Division of J&J. She was also the President of Asia Pacific for Synthes GmbH, the world leader in Orthopaedic trauma care. Before joining Synthes in 2004, she held several senior positions at Cochlear Limited in Product Development, Global Marketing and Education.
She also brings with her over 14 years of med tech expertise at GE Medical Systems spanning across Sales, Marketing and Management.
As the founder and CTO of Next Science, Dr. Matt Myntti oversees and manages all aspects of R&D and product ideation of Next Science technologies. He received his Master’s and Doctoral degrees in Materials Science and Engineering from the University of Dayton and has over 30 granted US patents. Dr. Myntti previously led the biomaterials group at Medtronic Surgical Technologies, which developed novel ENT and neurologic products.
Jon Swanson joined the Next Science team in June 2018 as the Chief Operating Officer to lead our operations, quality and regulatory teams. Mr. Swanson joins us from McKinsey & Co., where as the Head of the Advanced Operations Group, he focused on client operational improvement, product development and quality performance for pharma and medical product industries since 2011.
Prior to that, Mr. Swanson spearheaded manufacturing, product development and operational excellence at Medtronic in multiple leadership roles. As a professional rooted in operations and nuclear engineering excellence, he started his career in the US Navy. He holds a Master’s Degree in Business Administration from the University of Florida and a Bachelor’s Degree in Mathematics from the US Naval Academy.
Jacqueline Butler is the Chief Financial Officer at Next Science. She’s a certified Chartered Accountant from the Institute of Chartered Accountants, England and Wales (ICAEW) during her time at Arthur Andersen in London. She was in several financial roles in the UK and Europe and moved to Australia in 2005. She was the acting CFO for her client portfolio and the Head of Accounting and Financial Reporting Divisions as Associate Director at Azure Group Pty Ltd. She then went on to become the CFO and Company Secretary for Avira Energy Limited in 2013, helping to list the company on the ASX in 2013.
Mr. Daniel Canon is the VP, Operations at Next Science. As the former Senior Engineering Manager at Medtronic, he managed strategic company acquisitions, development and execution of subsequent business integration strategies to assure top notch medical device production quality.
An industry veteran with over 20 years of experience, Mr. Canon has lead complex projects in military, commercial, defense and medical operational environments. He has a Bachelor’s Degree in Electrical Engineering from Pennsylvania State University and a Master’s Degree in Mechanical Engineering from the University of Maryland.
Michael Morello is the Vice President of Wound Care Sales for Next Science. Mr. Morello is a graduate of Boston University and brings 25 years of experience in the Medical Device & Pharmaceutical Industries with an extensive focus in both the surgical and wound care sectors. Prior to joining Next Science, Mr. Morello has built and led several successful sales teams in both the commercial and federal spaces.
Jeanne Lee is the Vice President of Regulatory Affairs and Clinical Operations at Next Science. Ms. Lee brings over 20 years of global regulatory experience within the medical device and pharmaceutical industries, gained at leading companies including Hollister Incorporated, Abbott Laboratories and Merck & Co. Inc.. Ms. Lee holds a Master of Science degree in Regulatory Affairs and Quality Assurance from Temple University.
Robert Bell is the Vice President of Surgical Sales for Next Science. Mr. Bell has held various leadership roles within orthopedics, establishing distribution and subsidiaries globally, bringing 14 years of experience in the Medical Device and Orthopedics industries. With Next Science, Mr. Bell oversees the commercial operations via our industry partners and direct sales channels within the surgical sector.
Martyn Jacobs has over two decades of financial services experience, primarily in Equities Research covering emerging industrial companies, including the last decade with a focus on emerging healthcare companies. Mr. Jacobs enjoys detailed fundamental analysis to highlight the primary drivers of long-term economic value. He has a deep understanding of the Australian institutional investor universe and a focus on delivering outstanding client service levels for all stakeholders. Mr. Jacobs holds a Bachelor of Economics with post graduate qualifications in Applied Finance & Investment, as well as Applied Corporate Governance. Recently, Mr. Jacobs completed the AICD Company Directors Course, with membership status.
Many Dedicated Minds, with One Focus in Mind
With diverse, proven experience in research and development and bringing innovative technologies to market, our team has championed medtech innovation through the years. We are committed to improving public health through groundbreaking discoveries and effective solutions that combat antimicrobial resistance caused by biofilms.
Board of Directors
Sharing the same values and goals as everyone at Next Science, the members of our Board of Directors include industry executives with the knowledge, expertise and passion to help guide the company in fulfilling its mission.
Mark is Lord Prior of the International Order of St John and Chair of the Board of Trustees of St John International. Mark is Chair of Sonic Healthcare Limited (ASX: SHL), a global medical diagnostics and healthcare organization which is a Top 50 ASX listed entity. He is also Chair of St Luke’s Care Limited, a not for profit health and aged care organization and Chair of Integrated Clinical Oncology Network Pty Ltd trading as Icon Cancer Centre. Mark has held various CEO and managing director roles, including at St Luke’s Care Limited, Immune System Therapeutics Limited, Royal Flying Doctor Service of Australia, SciGen Limited and Alpha Healthcare Limited. He is an Adjunct Professor at Macquarie University in healthcare leadership and management (since 2012) and in 2010 was appointed a Member of the Order of Australia (AM) for his services to healthcare.
Judith Mitchell joined Next Science as CEO in August 2017. Previously Ms. Mitchell was President, DePuy Synthes Asia Pacific, the Orthopedics Division of J&J, holding the same role at Synthes GmbH prior to acquisition. Prior to that, Ms. Mitchell held various executive management roles at Cochlear and GE.
Bruce has over 35 years of corporate experience across a broad spectrum of commerce, including 16 years with Brierley Investments Limited in New Zealand. He held a number of senior roles at Brierley Investments as general manager and chair and served on the board of a number of their subsidiaries in New Zealand, Australia and the US.
Bruce has been a financial advisor to interests of Mr Langley Walker since 2008. He serves as a director of investments and wealth management at Walker Corporation Pty Ltd and works with the Walker group of companies to pursue investment opportunities outside the property market.
Dan is the CEO of iNova Pharmaceuticals (since 2017) which is a leading multinational consumer healthcare and pharmaceutical company with operations across Asia Pacific and Africa. Previously he was at Bausch Health (2011-2015) as Vice President and GM-North America (with responsibility for a portfolio of businesses spanning Vision Care, Dermatology and Aesthetic Devices) and was also Managing Director, Pacific region. Prior to that, Dan spent over 15 years at Johnson & Johnson Inc in various roles including Vice President, Country Manager, Chief Marketing Officer and other sales and marketing roles across the Asia Pacific, Europe/Middle East and North American regions.
Prior to joining Next Science, Aileen was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. She led Johnson & Johnson’s efforts to acquire Synthes for approximately $21 billion, Johnson & Johnson’s largest medical device acquisition. She also led the efforts to divest the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in numerous other M&A transactions including Pfizer Consumer Healthcare (US$16.5 billion), Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. Aileen is a Non-Executive Director of Microbot Medical Inc. (NASDAQ: MBOT)